Q-Line Biotech Key Ratios
NSE: QLINE
₹587.05
₹-8.50
(-1.43%)
As on 01-Sep-2026IST
Market cap
₹1,369 Cr
Revenue (TTM)
₹314 Cr
P/E Ratio
24.6
P/B Ratio
6.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- |
| Net Profit | -- | -- | -- | -- | -- |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| -- | -- | 21.41 | 16.76 | 17.30 |
| Net Margin
| -- | -- | 7.60 | 10.48 | 11.57 |
| Return on equity
| -- | -- | 13.94 | 14.97 | 16.79 |
| Return on Capital
| -- | -- | 19.19 | 16.07 | 16.76 |
| Return on Assets
| -- | -- | 6.18 | 7.34 | 8.52 |
| Debt to Equity (x)
| -- | -- | 0.88 | 0.60 | 0.58 |
Profitability
ROCE
19.19
Higher than Peers by 5.96
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
19.19
|
16.07
|
16.76
|
--
|
--
|
|
Peer Median
|
13.23
|
16.51
|
17.42
|
27.03
|
--
|
ROE
13.94
Lower than Peers by 0.09
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
13.94
|
14.97
|
16.79
|
--
|
--
|
|
Peer Median
|
14.03
|
12.58
|
14.29
|
18.94
|
--
|
ROA
6.18
Higher than Peers by 0.13
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
6.18
|
7.34
|
8.52
|
--
|
--
|
|
Peer Median
|
6.05
|
6.27
|
11.08
|
12.83
|
--
|
EBIT Margin
21.41
Higher than Peers by 9.49
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
21.41
|
16.76
|
17.30
|
--
|
--
|
|
Peer Median
|
11.92
|
17.72
|
10.64
|
19.57
|
--
|
Net Margin
7.60
Higher than Peers by 1.29
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
7.60
|
10.48
|
11.57
|
--
|
--
|
|
Peer Median
|
6.31
|
8.62
|
8.68
|
11.63
|
--
|
Cash Profit Margin
10.15
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
10.15
|
12.56
|
12.87
|
--
|
--
|
|
Peer Median
|
--
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
54.08
Higher than Peers by 34.79
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
54.08
|
11.44
|
--
|
--
|
--
|
|
Peer Median
|
19.29
|
35.34
|
69.01
|
251.95
|
--
|
EBIT Growth
96.77
Higher than Peers by 75.36
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
96.77
|
7.97
|
--
|
--
|
--
|
|
Peer Median
|
21.41
|
45.38
|
4,139.53
|
1,176.43
|
--
|
Net Profit Growth
13.27
Lower than Peers by 133.89
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
13.27
|
1.21
|
--
|
--
|
--
|
|
Peer Median
|
147.16
|
65.85
|
686.54
|
381.29
|
--
|
EPS Growth
-18.34
Lower than Peers by 165.50
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
-18.34
|
7.33
|
--
|
--
|
--
|
|
Peer Median
|
147.16
|
--
|
--
|
305.77
|
--
|
Book Value Growth
17.38
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
17.38
|
27.05
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.88
Higher than Peers by 0.56
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
0.88
|
0.60
|
0.58
|
--
|
--
|
|
Peer Median
|
0.32
|
0.48
|
0.12
|
0.10
|
--
|
Short term debt to equity ratio
0.29
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
0.29
|
0.31
|
0.43
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.48
Lower than Peers by 1.08
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
1.48
|
1.42
|
1.63
|
--
|
--
|
|
Peer Median
|
2.55
|
1.90
|
1.53
|
3.48
|
--
|
Quick Ratio
0.97
Lower than Peers by 11.13
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
0.97
|
0.67
|
1.23
|
--
|
--
|
|
Peer Median
|
12.10
|
1.77
|
2.22
|
2.71
|
--
|
Interest Coverage
3.98
Lower than Peers by 0.06
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
3.98
|
5.83
|
8.75
|
--
|
--
|
|
Peer Median
|
4.04
|
4.81
|
6.93
|
6.84
|
--
|
Operating Efficiency
Debtors to sales
26.32
Higher than Peers by 2.33
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
26.32
|
12.99
|
18.09
|
--
|
--
|
|
Peer Median
|
24.00
|
33.89
|
21.39
|
15.78
|
--
|
Asset Turnover
0.79
Lower than Peers by 0.14
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
0.79
|
0.69
|
0.73
|
--
|
--
|
|
Peer Median
|
0.94
|
1.29
|
0.86
|
0.79
|
--
|
Receivable days
63.42
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
63.42
|
53.32
|
66.03
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
113.68
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
113.68
|
133.38
|
87.08
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
143.90
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
143.90
|
194.12
|
163.82
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
33.20
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
33.20
|
-7.42
|
-10.72
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
20.16
|
51.65
|
61.00
|
61.43
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2.28
|
3.04
|
6.15
|
9.86
|
--
|
EV/EBITDA
1.45
Lower than Peers by 13.00
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
1.45
|
1.68
|
-0.41
|
--
|
--
|
|
Peer Median
|
14.45
|
25.55
|
11.25
|
17.58
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Q-Line Biotech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
252
|
126
|
36
|
46
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
